pradefovir
Small moleculeexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
1
Phase 4
0
Earliest trial started Jun 1, 2004 (NCT00230503)
Timeline
Indications
Studied for
Mechanism of action
- Hepatitis B virusINHIBITOR
Hepatitis B virus inhibitor
- DNA polymerase/reverse transcriptaseINHIBITOR
DNA polymerase/reverse transcriptase inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CS(=O)(=O)O.Nc1ncnc2c1ncn2CCOC[P@@]1(=O)OCC[C@@H](c2cccc(Cl)c2)O1- Mol. weight
- 519.9 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Prodrug
Sources
- ChEMBLCHEMBL3989658 ↗
- ChEMBLCHEMBL2111102 ↗
- ChEMBLCHEMBL2107363 ↗
- ChEMBLCHEMBL2096895 ↗
Also known as
- 9-(2-(4-(3-chlorophenyl)-2-oxo-1,3,2-dioxaphosphorinan-2-yl)methoxyethyl)adenine
- hepavir-b
- icn 2001-3
- icn-2001-3
- icn2001-3
- mb06866
- mb 06866
- mb-06866
- mb-6866
- pradefovir
- pradefovir
- pradefovir
- pradefovir mesilate
- pradefovir mesilate
- pradefovir mesylate
- pradefovir mesylate
- pradefovir mesylate
- pradefovir mesylate
- pradefovir mesylate
- remofovir
- remofovir mesylate
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04543565 | Phase 3 | Sep 30, 2020 | Jilin University, Xintong Pharmacy Company |
| NCT00230490 | Phase 2 | Jun 1, 2005 | Bausch Health Companies |
| NCT00230503 | Phase 2 | Jun 1, 2004 | Bausch Health Companies |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bausch Health Companies | For profit | 2 | 2 | 1 | 2004 |
| Jilin University | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Xintong Pharmacy Company | Government | 1 | 1 | 1 | 2020 |
3 organizations
Page 1 / 1